🔗 Share this article

While the United States proceeds with unprecedented changes to its vaccine schedules, a particular individual has emerged in a surprising turn: Høeg, a Danish American sports physician and public health researcher who rose to prominence by questioning Covid vaccinations in the pandemic and has focused upon possible deaths after Covid immunization in her brief position at the Food and Drug Administration.

Planned Shifts to Childhood Immunization Program

Agency leaders were set to announce major changes to the pediatric vaccination calendar in December, aligning the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of alignment with much of the international standard with insufficient data for public health gain. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Høeg is set to speak at the meeting. She was recently named acting director of the FDA’s CDER, the fifth person to lead the center this calendar year.

A Shift at the FDA

This interim role could signify a tighter collaboration between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has often pushed for ending some pediatric immunization guidelines in the US to become more in line with Denmark, a country with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

In her initial comments, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Qualifications

Høeg has little discernible experience in pharmaceutical research, oversight or leadership, which has been typical for past heads of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a sizeable institution. She is not an expert in drug approvals.”

Former commissioners of the center would “understand legal statutes and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that former directors who headed the center have had.”

CDER has an vast workload at the FDA, she emphasized.

“Everybody just zeroes in on the new drug program, but the off-patent medication office authorizes thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and more, and every single one need to be supervised,” Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major leadership aspect to the job, which manages in excess of 5,000 staff members. “It’s a enormous leadership role, if you execute it properly,” Woodcock concluded.

Agency Reaction and Contentious Initiatives

In response to questions about Dr. Høeg's qualifications and whether this selection represents more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “inquiries are based on flawed premises”.

“Her resume matches the functions of her role,” the representative explained, noting the months Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg takes over the agency head's controversial fast-track approval initiative, a disputed one-day drug-approval program that allegedly worried her former heads. “How are these therapies being picked for this fast-track system? Who makes the decisions?” Howard questioned. “There’s a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration appears to be shifting towards laxer rules of all drugs, aside from vaccines.”

Public Track Record on Vaccines

With immunizations, Dr. Høeg has a more documented, if concerning, history, critics observe. She released a study using non-validated volunteer-provided data to assess the frequency of myocarditis after Covid vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the current government included changing rules for novel immunizations and ending “optional” vaccines, she said after the election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of preventing young men from obtaining COVID-19 vaccines.

“She is an complete true believer who begins with her conclusions and reverse-engineers to retrofit the evidence in a extremely disingenuous, dishonest fashion,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg joined other contrarians, {like|